Retrovir Articles
ZIDOVUDINE REDUCED VERTICAL HIV SPREAD
28 February 1994
WELLCOME BOTTOMING OUT; IMPROVEMENT AHEAD
28 February 1994
MICROBIOLOGICA CUTS ZIDOVUDINE PRICE
21 February 1994
POSSIBLE TEST FOR HIV TRANSITION TO AIDS
14 February 1994
WELLCOME FACES ROCKY ROAD
7 February 1994
PROTEINASE INHIBITOR IN PHASE III TESTING
7 February 1994
CALL FOR US FDA AIDS DRUG COMMITTEE
7 February 1994
EUROPEAN STOCK COMMENT
7 February 1994
EUROPEAN STOCK COMMENT
31 January 1994
WINNERS AND LOSERS IN GLOBAL PHARMA INDUSTRY
31 January 1994
EUROPEAN STOCK COMMENT
24 January 1994
WELLCOME "TOO FOCUSED" FOR INDEPENDENCE
24 January 1994
WELLCOME SUED OVER RETROVIR
17 January 1994
B-MS SEEKS APPROVAL TO SELL STAVUDINE
17 January 1994
DRUG RESISTANT HIV PRESENTS A MAJOR STUMBLING BLOCK
10 January 1994
INCREASE IN NEW AIDS drugs IN TRIALS IN USA FOR 1993
10 January 1994
ZIDOVUDINE SCRIPTS DOWN AFTER CONCORDE
10 January 1994
ZOVIRAX ANOUNCEMENT
10 January 1994
IVAX SEES NICHEPRODUCTS AS ITS FUTURE
20 December 1993
ANTI-HIV, ALZHEIMER'S MARKET FORECASTS
20 December 1993
WORLD MARKET FOR ANTI-INFECTIVES
15 November 1993
ZOVIRAX PERFORMANCE: A WORRY FOR WELLCOME?
8 November 1993
AMPLIGEN KNOCKS OUT RESISTANT HIV
1 November 1993
WELLCOME RESULTS AS EXPECTED BUT US SLOWER
1 November 1993
3TC GAINS LIMITED CANADIAN APPROVAL
1 November 1993
FIALURIDINE TRIAL CASE HOTS UP
1 November 1993
US BIOTECH PRODUCTS IN R&D (Cont'd from last issue)
4 October 1993
US PANEL BACKS HIVID AS MONOTHERAPY...
4 October 1993
MERCK DISCONTINUES L661 DEVELOPMENT
20 September 1993
SINGAPORE CHARITY BUYS AIDS DRUGS
20 September 1993
ROCHE'S MISSES TARGET WITH TAT PROJECT
9 August 1993
RETROVIR TRIAL SPARKS DISPUTE
9 August 1993
EUROPEAN STOCK COMMENT
9 August 1993
NEW STUDY AFFIRMS RETROVIR VALUE
2 August 1993
WELLCOME'S RETROVIR PATENT UPHELD
2 August 1993
NICHE MARKETING IN THE BIOTECH INDUSTRY
26 July 1993
WELLCOME NOT JUST AN ANTIVIRAL COMPANY?
19 July 1993
SPAIN LICENSES DIDANOSINE
12 July 1993
WELLCOME PATENT "STRONG CASE"?
12 July 1993
EUROPEAN STOCK COMMENT
12 July 1993
US NIH ON FENCE OVER EARLY-STAGE RETROVIR
5 July 1993
VARIED VIEWS ON WELLCOME'S PROFIT OUTLOOK
5 July 1993
EUROPEAN STOCK COMMENT
28 June 1993
NOVEL HIV ANTIVIRALS IN DEVELOPMENT
28 June 1993
WELLCOME HALTS FLOLAN DEVELOPMENT FOR CHF
28 June 1993
COMBINATION THERAPIES IN AIDS: LITTLE PROGRESS
21 June 1993
NNRT INHIBITORS IN CLINICAL DEVELOPMENT
21 June 1993
ACTG 076 ZIDOVUDINE IN CHILDREN RESULTS
21 June 1993
EUROPE STOCK COMMENT
14 June 1993
CUT IN ZIDOVUDINE USE URGED
14 June 1993
BREFELDIN A IN HIV
17 May 1993
TOKYO STOCK COMMENT
17 May 1993
ZIDOVUDINE IN JAPAN
10 May 1993
WELLCOME REFOCUSING R&D EFFORTS
10 May 1993
VEREX IMPROVES ZIDOVUDINE ACTION
10 May 1993
RETROVIR-RESISTANT HIV TRANSMITTED
3 May 1993
US NIH INABILITY TO ENFORCE FAIR PRICING
3 May 1993
TOKYO STOCK COMMENT
26 April 1993
DRUG FIRMS TO WORK TOGETHER ON AIDS R&D
26 April 1993
LARGE-SCALE US TB TRIAL PLANNED
26 April 1993
LONDON STOCK COMMENT
12 April 1993
WELLCOME SPEAKS ON EARLY-USE RETROVIR
12 April 1993
STUDY CASTS DOUBT ON RETROVIR IN EARLY AIDS
12 April 1993
US HIV-TRIAL FOR ROCHE'S RO 31-8959
5 April 1993
UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS
5 April 1993
WELLCOME INTERIMS DRIVEN BY ZOVIRAX
29 March 1993
NEW DATA ON ZIDOVUDINE, ACICLOVIR COTHERAPY
29 March 1993
ANTI-HIV MONOCLONAL ANTIBODY DISCOVERY
22 March 1993
ZENECA SETTLES US PATENT DISPUTE
22 March 1993
IS GOVT GETTING ITS RESEARCH REWARDS?
8 March 1993
JANSSEN TO PRESS ON WITH R 89439 DEV'T
8 March 1993
FRENCH MOVES ON VIRAL DISEASES
8 March 1993
TRIPLE THERAPY FOR HIV INFECTION
1 March 1993
SANDOZ DEAL WITH SCRIPPS QUESTIONED
22 February 1993
TREAT HIV EARLY, SAYS MEETING
15 February 1993
ROCHE UNDER FIRE FROM AIDS ACTIVIST GROUPS
15 February 1993
KANEMATSU TO MARKET THYMIDINE
8 February 1993
HONG KONG DOCTOR CLAIMS AIDS FINDING
8 February 1993
HIVID AND VIDEX SHOW SIMILAR BENEFITS
1 February 1993
FURTHER ANTIVIRAL EFFECT OF RETROVIR?
25 January 1993
RESISTANCE TO ZIDOVUDINE UP?
18 January 1993
RELATIVE BENEFIT OF RETROVIR AND VIDEX
4 January 1993
EUROPE STOCK COMMENT
4 January 1993
WELLCOME AIDS DRUG DEAL IN CANADA
4 January 1993
IVAX ALMOST "FULLY FLEDGED DRUG CO"
21 December 1992
WELLCOME'S US "TIDAL WAVE" REVERSING?
21 December 1992
CAN DIDANOSINE DOSE BE SLASHED?
14 December 1992
NIH INPUT VALUE IN CRADA PRICES
14 December 1992
INDIAN MIFEPRISTONE PRODUCTION
7 December 1992
ABBREVIATED DRUG NAMES WARNING
7 December 1992
INDIAN AIDS DRUG TECH FOR BRAZIL
7 December 1992
COUNTING THE COST OF SCHIZOPHRENIA
7 December 1992
WELLCOME PRETAX PROFITS RISE 25%
2 November 1992
US SCIENTISTS FIND ANTI-TOXIC AGENT
12 October 1992
EXPANDED ACCESS TO STAVUDINE
12 October 1992
STOCK MARKET COMMENTARY: TOKYO
12 October 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
US APPROVES VIDEX FOR EXPANDED USE
5 October 1992
NORTH AMERICAN NEWS IN BRIEF
7 September 1992
DIDANOSINE BETTER THAN ZIDOVUDINE IN HIV?
7 September 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
